AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27397060
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (Ins)
Trial: 25418987
Drug: PEG-asparaginase (Oncaspar®)
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose administered intramuscularly at 2 or 6 weeks intervals for a total of 30 weeks
Trial: 25418987
Drug: Erwinase therapy
RxNorm normalized name: Erwinaze
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erwinase therapy
Trial: 19105270
Drug: Chinese traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese traditional medicine (oral administration)
Trial: 19105270
Drug: Celecoxib and
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib and glucosamine hydrochloride (oral administration)
Trial: 11284464
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care medications
Trial: 7870724
Drug: Radionuclide methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radionuclide methods (infusion dynamic ureteroscintigraphy, dynamic and static scintigraphy of the kidneys, radionuclide renography)
Trial: 25058845
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI), 100/25 μg, delivered via ELLIPTA dry powder inhaler, administered once daily
Trial: 25058845
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide (TIO), 18 μg, administered once daily
Trial: 19923528
Drug: IV propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV propofol infusion (2.4 mg/kg)
Trial: 15477492
Drug: Randomized study
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized study of two regimens for the last 4 months of treatment (n = 1,075)
Trial: 15477492
Drug: Twice-weekly rifabutin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly rifabutin-containing regimen for HIV-infected tuberculosis (n = 169)
Trial: 11452678
Drug: Amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate (875 mg twice daily)
Trial: 9549518
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IV Ig) treatment (0.4 g/kg for 5 consecutive days)
Trial: 9549518
Drug: IV Ig
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Ig maintenance treatment (one infusion every week for 2-4 years)
Trial: 9549518
Drug: Incidental IV
RxNorm normalized name: POTASSIUM NITRATE 3.75 g in 100 g / SODIUM MONOFLUOROPHOSPHATE 0.76 g in 100 g / CETYLPYRIDINIUM CHLORIDE 0.3 g in 100 g DENTAL PASTE, DENTIFRICE [Unidental All CareToothpaste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidental IV Ig treatment when muscle strength deteriorated
Trial: 8311557
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - transdermal oestradiol patches twice weekly for 48 weeks plus norithisterone tablets when clinically indicated
Trial: 28208713
Drug: Encapsulated fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated fruit and vegetable juice concentrate (6 capsules daily for 8 weeks)
Trial: 19106250
Drug: 24-h fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h fast with acipimox (250 mg)
Trial: 14746858
Drug: rIFN-gamma (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma (0.2 mg, subcutaneously every other day for 12 months)
Trial: 3092711
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patches (5, 10, and 20 mg per 24 hours)
Trial: 19064019
Drug: Rosuvastatin (1:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (1:1 dose ratio)
Trial: 19064019
Drug: Rosuvastatin (1:2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (1:2 dose ratio)
Trial: 19064019
Drug: Rosuvastatin (1:4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (1:4 dose ratio)
Trial: 19064019
Drug: Atorvastatin (1:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (1:1 dose ratio)
Trial: 19064019
Drug: Atorvastatin (1:2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (1:2 dose ratio)
Trial: 19064019
Drug: Atorvastatin (1:4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (1:4 dose ratio)
Trial: 11072457
Drug: 2-mg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg sublingual nicotine tablets
Trial: 4028617
Drug: Amoxycillin 375
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 375 mg
Trial: 4028617
Drug: Amoxycillin 750
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 750 mg
Trial: 4028617
Drug: Amoxycillin 1500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1500 mg
Trial: 389824
Drug: Bacampicillin 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 1600 mg
Trial: 29732978
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 4 g for 1 hour followed by 1 g over 6 hours infusion
Trial: 24929455
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 injection of methylprednisolone acetate)
Trial: 22681971
Drug: 0.2 μg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/kg/h intravenous dexmedetomidine
Trial: 22681971
Drug: 0.4 μg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 μg/kg/h intravenous dexmedetomidine
Trial: 22681971
Drug: 0.6 μg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 μg/kg/h intravenous dexmedetomidine
Trial: 15677598
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus medication
Trial: 9934807
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg per day
Trial: 268332
Drug: Chlorhexidine mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthrinse once daily (Group A in maxillary areas)
Trial: 268332
Drug: Localized plaque
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized plaque accumulation with no oral hygiene (control)
Trial: 28275131
Drug: Catechin beverage
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catechin beverage (615 mg catechin and 77 mg caffeine)
Trial: 28275131
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage (82 mg caffeine)
Trial: 28275131
Drug: Catechin beverage
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catechin beverage (daily ingestion for 5 weeks)
Trial: 28275131
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage (daily ingestion for 5 weeks)
Trial: 21342355
Drug: 20% olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% olive oil-based intravenous lipid emulsion (ILE)
Trial: 21342355
Drug: 20% soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% soybean oil-based intravenous lipid emulsion (ILE)
Trial: 19226569
Drug: 1,450 nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,450 nm diode laser treatment
Trial: 17126585
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose corticosteroid treatment (8-12 weeks)
Trial: 11322354
Drug: Fibromyalgia Treatment
RxNorm normalized name: Aconitum napellus/Arnica montana Radix/Autumn Crocus/Barberry/Bryonia/Devil's Claw Root/Marsh Tea/Rhododendron Chrysanthum/Rhus Toxicodendron/Valerian/Woody Nightshade 4 X-3 X-6 X-6 X-4 X-6 X-6 X-6 X-4 X-2 X-6 X Oral Tablet, Disintegrating [FIBROMYALGIA SYMPTOM RELIEF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibromyalgia Treatment Program
Trial: 9385869
Drug: Invisible spatial
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisible spatial transformations with varying orientation cues, path of motion, and amount of transformation; specific details on dosage and duration not applicable.
Trial: 7899788
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg x 3 daily
Trial: 7899788
Drug: Albendazole 1200
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 1200 mg x 3 daily
Trial: 7899788
Drug: Albendazole administered
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole administered 5-7 days after ivermectin
Trial: 3110848
Drug: d-amphetamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.5 mg/kg PO)
Trial: 29116126
Drug: Clinical predictors
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical predictors including demographics, anthropometrics, cardiac and blood measures, diet and exercise, physical and mental health, medication
Trial: 29116126
Drug: Genetic polygenic
RxNorm normalized name: polygalic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic polygenic risk scores (PRS) for schizophrenia, bipolar disorder, BMI, waist‐hip‐ratio, insulin resistance and height, gene co‐expression modules from WGCNA
Trial: 23331081
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration (BI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine.
Trial: 23331081
Drug: Buccal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal plus lingual infiltration (BLI) group: 40 patients received supplemental BI of 0.9 mL of 4% articaine with 1 : 100,000 epinephrine and LIs with the same anaesthetic solution and dose.
Trial: 17143239
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (both types)
Trial: 9387969
Drug: Tetracycline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (1.5 g)
Trial: 9387969
Drug: Bleomycin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (60 mg)
Trial: 7910473
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg day‐1)
Trial: 7910473
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg day‐1)
Trial: 7910473
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg day‐1)
Trial: 25716362
Drug: Whole-brain radiotherapy
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiotherapy (WBRT) after high-dose methotrexate (HDMTX)-based chemotherapy
Trial: 25716362
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX)-based chemotherapy alone
Trial: 21714640
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of parenteral nutrition (not initiated before day 8)
Trial: 29570588
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of parenteral nutrition
Trial: 21714640
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of parenteral nutrition (initiated within 48 hours after ICU admission)
Trial: 15342289
Drug: Nesiritide infusions
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide infusions at dosages of 0.005 or 0.01 microg/kg/min for 12 weeks
Trial: 1390333
Drug: Intravenous bepridil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bepridil (2 mg/kg)
Trial: 1390333
Drug: Oral bepridil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bepridil (500 mg/day)
Trial: 1390333
Drug: Oral bepridil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bepridil (900 mg/day)
Trial: 1390333
Drug: Oral bepridil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bepridil (300 mg/day)
Trial: 1390333
Drug: Oral bepridil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bepridil (600 mg/day)
Trial: 3935405
Drug: Insulin-glibenclamide combination
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-glibenclamide combination therapy
Trial: 30964413
Drug: Anopheles gambiae
RxNorm normalized name: ANOPHELES QUADRIMACULATUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anopheles gambiae s.l. in rural areas
Trial: 29117299
Drug: High-dose triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose triamcinolone acetonide (40 mg)
Trial: 29117299
Drug: Low-dose triamcinolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose triamcinolone acetonide (20 mg)
Trial: 8659199
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 80 mg/day
Trial: 24851040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isosorbide dinitrate and ibuprofen
Trial: 22892744
Drug: 2% gel
RxNorm normalized name: SULFUR 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% gel CHX
Trial: 20159177
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone for 168 days
Trial: 20159177
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of 30 mcg ethinylestradiol and 3 mg drospirenone
Trial: 20159177
Drug: Cyclic use
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone for six 28‐day cycles
Trial: 20159177
Drug: Cyclic use
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic use of 30 mcg ethinylestradiol and 3 mg drospirenone
Trial: 17646619
Drug: 10-cm² rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10-cm² rivastigmine patch (9.5 mg/24 hours)
Trial: 17646619
Drug: 20-cm² rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20-cm² rivastigmine patch (17.4 mg/24 hours)
Trial: 17646619
Drug: 6-mg BID
RxNorm normalized name: sarolaner 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mg BID rivastigmine capsules
Trial: 15789954
Drug: Corrective treatment
RxNorm normalized name: SALICYLIC ACID 0.5 mg in 90 mL TOPICAL CLOTH [Clear Future Corrective Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrective treatment
Trial: 9506733
Drug: Methimazole plus
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole plus T4 to suppress TSH below 0.6 mIU/L (group 3)
Trial: 6579838
Drug: Intracervical application
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical application of 0.5 mg of prostaglandin E2 (PGE2) in 2 ml of gel
Trial: 6579838
Drug: Intravaginal application
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal application of 4 mg of prostaglandin E2 (PGE2) in 3 ml of gel
Trial: 31898663
Drug: 6 fractions/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 fractions/week of RT (46 Gy/23 fractions/26 days) with injection Cisplatin 40 mg/m2
Trial: 31898663
Drug: 5 fractions/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 fractions/week of RT (46 Gy/23 fractions/31 days) with injection Cisplatin 40 mg/m2
Trial: 26871847
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 μg/kg loading dose over 10 minutes, followed by 0.5 μg/kg/h maintenance)
Trial: 18609169
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily treatment with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B(6) for 4 months
Trial: 7599749
Drug: Enalapril (1.0-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (1.0-1.2 mg intravenous over 1-2 hours)
Trial: 1741918
Drug: 750 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/d oxytetracycline over a fortnight
Trial: 28397754
Drug: Colostrum bovinum
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum bovinum supplementation (500 mg for 20 days)
Trial: 19154574
Drug: Sci-B-Vac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sci-B-Vac vaccine (2.5 microg)
Trial: 19154574
Drug: Sci-B-Vac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sci-B-Vac vaccine (5.0 microg)
Trial: 19154574
Drug: Sci-B-Vac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sci-B-Vac vaccine (2.5 microg or 5.0 microg)
Trial: 15190957
Drug: IC14 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (1 mg/kg or 4 mg/kg single doses; 4 mg/kg daily for 4 days; or 4 mg/kg on day 1 followed by 2 mg/kg daily for 3 days)
Trial: 9886901
Drug: tasosartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasosartan (100 mg/day)
Trial: 2308263
Drug: Propranolol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (a nonselective beta-1, beta-2 antagonist) during exercise
Trial: 2308263
Drug: Metoprolol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (a specific beta-1 antagonist) during exercise
Trial: 380256
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 mg, 1-2 tablets as needed, max 5 tablets daily)
Trial: 29999203
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with real-time visual feedback
Trial: 29999203
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy without real-time visual feedback
Trial: 25579161
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (G group, n=27)
Trial: 16036036
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human BNP (nesiritide) as an intravenous treatment for acute decompensated HF
Trial: 31286734
Drug: Acupoint thread-embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread-embedding therapy (operated once every 30 days, total of 2 treatments)
Trial: 31286734
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tears eye drops (4 to 6 times a day, one drop each time, for 8 weeks)
Trial: 16753012
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg daily
Trial: 26639957
Drug: Bapineuzumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 0.5 mg/kg in carriers
Trial: 26639957
Drug: Bapineuzumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 1.0 mg/kg in noncarriers
Trial: 26639957
Drug: Bapineuzumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 0.5 mg/kg in noncarriers
Trial: 23872837
Drug: Fruit-flavoured jelly
RxNorm normalized name: FLAVOR,FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit-flavoured jelly containing 4 g of agar crystals
Trial: 20002369
Drug: 1000 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 microg of self‐administered vaginal misoprostol
Trial: 20002369
Drug: Self‐administered vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered vaginal placebo
Trial: 19025528
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil in ropivacaine (0.015 mcg/kg/ml sufentanil in 1.5 mg/ml ropivacaine, infused at 2 ml/h)